Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
|
28474247 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II), an effective component of renin-angiotensin system, plays a pivotal role in cardiac fibrosis, which may further contribute to heart failure.
|
30369577 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Opposite Effects of Moderate and Extreme Cx43 Deficiency in Conditional Cx43-Deficient Mice on Angiotensin II-Induced Cardiac Fibrosis.
|
31652649 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition.
|
30670148 |
2019 |
Cardiac fibrosis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Angiotensin II stimulates cardiac fibrosis and conduction heterogeneity.
|
19648063 |
2009 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next, we investigated the effects of lncRNA FAF on angiotensinogen II (Ang II)-induced cardiac fibrosis in neonatal rat CFs and explored the mechanism underlying these effects.
|
31708099 |
2020 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endogenous Insl6 protein inhibits cardiac systolic dysfunction and cardiac fibrosis in angiotensin II- and isoproterenol-induced cardiac stress models.
|
29887522 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that macrophages when recruited into the heart and aorta from the spleen potentially contribute to angiotensin II-induced cardiac fibrosis and hypertension.
|
28490219 |
2018 |
Cardiac fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.
|
25898844 |
2015 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice in which αv integrin is depleted in PDGFRβ<sup>+</sup> cells are protected from cardiotoxin and laceration-induced skeletal muscle fibrosis and angiotensin II-induced cardiac fibrosis.
|
29061963 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Echocardiographic analysis, Sirius Red staining and immunofluorescence staining were performed to investigate the function of circHIPK3 in angiotensin II (Ang II) induced cardiac fibrosis in vivo.
|
30967276 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of histopathological analysis, as well as measurements of collagen expression and cardiac fibroblast proliferation indicated that puerarin administration significantly inhibited cardiac fibrosis induced by AB and AngII.
|
29928229 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protocatechuic acid attenuates angiotensin II-induced cardiac fibrosis in cardiac fibroblasts through inhibiting the NOX4/ROS/p38 signaling pathway.
|
31318113 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we found that A77 1726 treatment attenuated pressure overload or angiotensin II (Ang II)-induced cardiac hypertrophy <i>in vivo</i>, as well as agonist-induced hypertrophic response of cardiomyocytes <i>in vitro</i> In addition, we showed that A77 1726 administration prevented induction of cardiac fibrosis by inhibiting cardiac fibroblast (CF) transformation into myofibroblast.
|
29540538 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD44 Deficiency in Mice Protects the Heart Against Angiotensin Ii-Induced Cardiac Fibrosis.
|
29470359 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with anti-IL-16 neutralizing antibody ameliorated cardiac fibrosis in the mouse model of angiotensin II-induced hypertension.
|
23894370 |
2013 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe the use a highly selective TG2 small-molecule inhibitor to test the efficacy of TG2 inhibition as an anti-fibrotic therapy for heart failure employing two different in vivo models of cardiac fibrosis: Progressively induced interstitial cardiac fibrosis by pressure overload using angiotensin II infusion: Acutely induced focal cardiac fibrosis through myocardial infarction by ligation of the left anterior descending coronary artery (AMI model).
|
29795262 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of microRNA‑155 ameliorates cardiac fibrosis in the process of angiotensin II‑induced cardiac remodeling.
|
28944921 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erratum to: Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
|
29030734 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Steroidogenic acute regulatory protein/aldosterone synthase mediates angiotensin II-induced cardiac fibrosis and hypertrophy.
|
31820314 |
2020 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (AngII) has been implicated in the development of cardiac fibrosis.
|
31640463 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-29b plays a protective role in AngII-mediated cardiac remodeling and may be a therapeutic agent for cardiac fibrosis by targeting the TGF-β/Smad3 pathway.
|
24569834 |
2014 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results together reveal that IMM-H007 improves heart function, and alleviates AngII-induced cardiac fibrosis by regulating AMPK-TGF-β1 signaling.
|
31181209 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease.
|
20157054 |
2010 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-to-mesenchymal transition (EndMT) is a mechanism that promotes cardiac fibrosis induced by Angiotensin II (AngII).
|
29073623 |
2017 |